| Literature DB >> 36064407 |
Xiaoli Wu1,2, Junye Liu1, Hongpeng Zhang3,4, Hua Zhou5, Wen Wang1, Yuanyan Ma1, Shimei Shen1, Xuefei Cai1, Ailong Huang1, Deqiang Wang6,7.
Abstract
BACKGROUND: Effective therapeutics and vaccines for coronavirus disease 2019 (COVID-19) are currently lacking because of the mutation and immune escape of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on the propagation characteristics of SARS-CoV-2, rapid and accurate detection of complete virions from clinical samples and the environment is critical for assessing infection risk and containing further COVID-19 outbreaks. However, currently applicable methods cannot achieve large-scale clinical application due to factors such as the high viral load, cumbersome virus isolation steps, demanding environmental conditions, and long experimental periods. In this study, we developed an immuno molecular detection method combining capture of the viral spike glycoprotein with monoclonal antibodies and nucleic acid amplification via quantitative reverse transcription PCR to rapidly and accurately detect complete virions.Entities:
Keywords: COVID-19; Complete virions; Immunomolecular detection; Infection risk; Spike
Mesh:
Substances:
Year: 2022 PMID: 36064407 PMCID: PMC9444083 DOI: 10.1186/s12951-022-01558-8
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 9.429
Fig. 1Construction of pseudo-SARS-CoV-2 virus and screening of specific antibodies directed to spike proteins. a Structures of SARS-CoV-2 and the SARS-CoV-2 pseudovirus. b Infectivity of SARS-CoV-2 pseudovirus. HEK-293FT-hACE2 cells transduced with VSV pseudovirus encoding GFP were used as a positive control. c Detection of SARS-CoV-2 S protein incorporated in lentivirus via western blotting. The wild-type spike glycoprotein overexpressed in 293 cells and VSV pseudovirus without spike glycoprotein were used as the positive control and the negative control, respectively. d Detection of target sequence synthesized and cloned in SARS-CoV-2 lentivirus via RT-qPCR using a 2019-nCoV nucleic acid detection kit (Sansure Bio, China). The VSV pseudotype virus was prepared using the same procedure without the target sequence taken as the negative sample. e Identification of potential antibodies binding to the polypeptide fragment of spike glycoproteins via western blot with the lysate of SARS-CoV-2 pseudovirus after heating for 10 min at 100 °C. The SARS-CoV-2 S protein expressed via 293T cells transfected with vector-encoded wild-type SARS-CoV-2 S glycoprotein used as a control. f. Identification of potential antibodies binding to the active Spike glycoproteins of SARS-CoV-2 through the particle gel with pseudovirus resuspension. The VSV pseudotype virus was prepared suing the same procedure and used as a negative control
Fig. 2Establishment of immunocapture‐based SARS-CoV-2 pseudovirus detection platform. a Flow diagram of immunocapture-based SARS-CoV-2 pseudovirus detection platform. b Protein concentration of carboxyl magnetic bead-antibody complexes following conjugation evaluated in a BCA assay. c. Particle size analysis of carboxy magnetic beads (MB) and magnetic beads coupled with a CQ25 antibody (MB-CQ25) (****, P < 0.0001). d Optimization of the antibody required for conjugation with beads. Carboxyl magnetic beads coupled with a CQ25 antibody and corresponding supernatant were detected using SDS-PAGE. e SARS-CoV-2 pseudovirus captured via carboxyl magnetic beads coupled with a CQ25 antibody was detected using a particle gel assay with anti-HIV1 P24 antibodies. f The real-time fluorescence quantitative amplification targeted to the F1ab. Multiple viruses captured via CQ25 antibody-coupled carboxyl magnetic beads were detected using qRT-PCR with a 2019-nCoV nucleic acid detection kit (Sansure Bio)
Fig. 3Detection target of immune molecular method is only intact virus particles. a Levels of spike glycoprotein of SARS-CoV-2 pseudovirus in each gradient fraction analyzed by the western blotting and particle gel assay using anti-spike (S2) antibodies, respectively. b Levels of F1ab gene of SARS-CoV-2 pseudovirus in each gradient fraction analyzed via qRT-PCR and immunomolecular assay, respectively. c Infectious activity corresponding to different titers of complete virions
Fig. 4Validation of immunomolecular assay for intact SARS-CoV-2 particles. a Linear regression for the assay. When the SARS-CoV-2 pseudovirus titer ranged between 6 × 102 and 6 × 107 TU/mL, a linear relationship occurred between the quantification Cq value and its titer (log-transformed) in the immunomolecular assay. y = − 2.537x + 40.02, R2 = 0.99. b Specificity of the assay. Twenty-four of the carboxyl magnetic beads with CQ25 antibody complexes (MB-CQ25) and 24 captured pseudovirus samples were used to evaluate the assay specificity. ****P < 0.0001. c Interference from HBV supernatant from AD38 cells and patient serum with different titers of HBV. d SARS-CoV-2 pseudovirus stability under different conditions. Viruses were applied to copper, aluminum, paper, and plastic maintained at 21–23 °C and 40% relative humidity over seven days. The titer of viable virus was expressed as log10-tranformed. Plots show the means and standard errors (I bars) of three replicates